Article Details

Fosun Pharma and Henlius Entered into an Exclusive License Agreement for Serplulimab in the US

Retrieved on: 2023-01-07 17:23:43

Tags for this article:

Click the tags to see associated articles and topics

Fosun Pharma and Henlius Entered into an Exclusive License Agreement for Serplulimab in the US. View article details on hiswai:

Excerpt

We have been practicing internationalization strategies in the dimensions of innovative R&D, license introduction, production operation and ...

Article found on: pipelinereview.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up